Vestal Point Capital LP Takes $666,000 Position in Traws Pharma, Inc. (NASDAQ:TRAW)

Vestal Point Capital LP acquired a new stake in shares of Traws Pharma, Inc. (NASDAQ:TRAW) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 75,000 shares of the company’s stock, valued at approximately $666,000. Vestal Point Capital LP owned 2.05% of Traws Pharma as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in TRAW. Alyeska Investment Group L.P. purchased a new stake in shares of Traws Pharma during the fourth quarter valued at approximately $1,036,000. Boothbay Fund Management LLC purchased a new stake in shares of Traws Pharma during the fourth quarter valued at approximately $252,000. Geode Capital Management LLC acquired a new stake in shares of Traws Pharma during the fourth quarter worth approximately $185,000. Renaissance Technologies LLC acquired a new stake in shares of Traws Pharma during the fourth quarter worth approximately $89,000. Finally, Millennium Management LLC acquired a new stake in shares of Traws Pharma during the fourth quarter worth approximately $89,000. Hedge funds and other institutional investors own 7.95% of the company’s stock.

Traws Pharma Trading Up 8.2%

TRAW stock opened at $1.19 on Monday. Traws Pharma, Inc. has a twelve month low of $0.97 and a twelve month high of $19.44. The company has a market capitalization of $6.35 million, a P/E ratio of -0.01 and a beta of 1.59. The firm has a 50 day simple moving average of $1.95 and a 200-day simple moving average of $4.60.

Traws Pharma (NASDAQ:TRAW) last released its quarterly earnings results on Wednesday, May 21st. The company reported $2.09 earnings per share for the quarter, topping analysts’ consensus estimates of ($8.04) by $10.13. The company had revenue of $0.06 million for the quarter, compared to analyst estimates of $0.06 million.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.